The accelerated SARS-CoV-2 evolution under selective pressure by massive deployment of
neutralizing antibody-based therapeutics is a concern with potentially severe implications for …

Ever since the breakout of COVID-19 disease, ceaseless genomic research to inspect the
epidemiology and evolution of the pathogen has been undertaken globally. Large scale viral …

Antibodies elicited in response to infection undergo somatic mutation in germinal centers
that can result in higher affinity for the cognate antigen. To determine the effects of somatic …

Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …

Although neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of
most COVID-19 vaccines and being developed as therapeutics, escape mutations could …

Somatic hypermutation (SHM) drives affinity maturation and continues over months in SARS-
CoV-2-neutralizing antibodies (nAbs). However, several potent SARS-CoV-2 antibodies …

The global pandemic of the coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), places a heavy burden on global public …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern
(VOCs), harboring spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) …

Despite the efficacy of antiviral drug repositioning, convalescent plasma (CP), and the
currently available vaccines against severe acute respiratory syndrome coronavirus 2 …

Background The role of host immunity in emergence of evasive SARS-CoV-2 Spike
mutations under therapeutic monoclonal antibody (mAb) pressure remains to be explored …